Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, October 11 '25)

Image
By G.M.

 


    Ann Intern Med

  1. LE VU M, Matthes KL, Schneider EB, Moerlen A, et al
    Maternal Influenza-Like Illness and Neonatal Health During the 1918 Influenza Pandemic in a Swiss City.
    Ann Intern Med. 2025 Oct 7. doi: 10.7326/ANNALS-24-03796.
    PubMed         Abstract available


    Antiviral Res

  2. SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al
    Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.
    Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286.
    PubMed         Abstract available


    Epidemiol Infect

  3. VAN DER ROEST B, Fischer EAJ, Klinkenberg D, Bootsma MCJ, et al
    Phylodynamic inference suggests introductions as main driver of Mpox Clade II outbreak in 2022 in Slovenia.
    Epidemiol Infect. 2025;153:e115.
    PubMed         Abstract available

  4. WOLDEGIORGIS M, Bloomfield L, Korda R, Cadby G, et al
    Factors associated with persistence or recovery from long COVID 6 months post-SARS-CoV-2 infection.
    Epidemiol Infect. 2025;153:e116.
    PubMed         Abstract available


    J Epidemiol Community Health

  5. ROMANO CJ, Nianogo RA, Hoover C, Quint JJ, et al
    Evaluating the effect of the end of the COVID-19 uninsured programme on COVID-19 vaccine administration in California: a quasi-experimental study.
    J Epidemiol Community Health. 2025;79:821-827.
    PubMed         Abstract available


    J Exp Med

  6. CHANGROB S, Yasuhara A, Park S, Bangaru S, et al
    Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2.
    J Exp Med. 2025;222:e20251146.
    PubMed         Abstract available


    J Infect

  7. FOULKES S, Munro K, Sparkes D, Khawam J, et al
    Prevalence and impact of SARS-CoV-2, influenza, respiratory syncytial virus (RSV) infection and respiratory illness on UK healthcare workers during winter 2023/24 (September 2023 to March 2024): SIREN cohort study.
    J Infect. 2025;91:106620.
    PubMed         Abstract available


    J Virol

  8. SHETTY N, Shephard MJ, Rockey NC, Macenczak H, et al
    Correction for Shetty et al., "Influenza virus infection and aerosol shedding kinetics in a controlled human infection model".
    J Virol. 2025 Oct 7:e0135425. doi: 10.1128/jvi.01354.
    PubMed        


    PLoS Comput Biol

  9. O'NEILL X, White A, Northrup GR, Saad-Roy CM, et al
    Superspreading and the evolution of virulence.
    PLoS Comput Biol. 2025;21:e1013517.
    PubMed         Abstract available

  10. TEITELBAUM CS, Casazza ML, Overton CT, Matchett EL, et al
    Host responses and viral traits interact to shape the impacts of climate warming on highly pathogenic avian influenza in migratory waterfowl.
    PLoS Comput Biol. 2025;21:e1013451.
    PubMed         Abstract available

  11. PINETTES T, Leclerc QJ, Jean K, Temime L, et al
    The quarantine hospital strategy as a way to reduce both community and nosocomial transmission in the context of a COVID-like epidemic.
    PLoS Comput Biol. 2025;21:e1013548.
    PubMed         Abstract available

  12. STEYN N, Chadeau-Hyam M, Elliott P, Donnelly CA, et al
    A Bayesian model for repeated cross-sectional epidemic prevalence survey data.
    PLoS Comput Biol. 2025;21:e1013515.
    PubMed         Abstract available

  13. DU H, Zahn MV, Loo SL, Alleman TW, et al
    Improving policy design and epidemic response using integrated models of economic choice and disease dynamics with behavioral feedback.
    PLoS Comput Biol. 2025;21:e1013549.
    PubMed         Abstract available


    PLoS Med

  14. LEWNARD JA, Malden DE, Hong V, Skela J, et al
    Comparative risk of post-acute sequelae among adults following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults.
    PLoS Med. 2025;22:e1004777.
    PubMed         Abstract available


    PLoS One

  15. LOMELI A, Escoto AA, Reyes B, Kornher K, et al
    Sources of successful participant engagement in a public health research study: A focus on a Latino community.
    PLoS One. 2025;20:e0321910.
    PubMed         Abstract available

  16. TITUS AR, Kanchi R, Adhikari S, Thorpe LE, et al
    Time-varying associations between diabetes and mortality following COVID-19: Evidence from a U.S. Veteran population.
    PLoS One. 2025;20:e0333052.
    PubMed         Abstract available

  17. LIU HH, Battaglia J, Wu TT
    Impact of COVID-19 on English Football Premier League: Analyzing rankings and home advantage using extended Bradley-Terry models.
    PLoS One. 2025;20:e0332627.
    PubMed         Abstract available

  18. MILLER EM, Boyce RM, Kipp AM, Newby LK, et al
    Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 - February 2022.
    PLoS One. 2025;20:e0332645.
    PubMed         Abstract available

  19. REVELJ M, Wessberg A, Carlsson Y, Lindqvist M, et al
    Reclaiming motherhood through shame, distance, and gratitude-A phenomenological study of Swedish women's lived experiences of giving birth while ill with COVID-19.
    PLoS One. 2025;20:e0333937.
    PubMed         Abstract available

  20. LAN WY, Cai SS, Lu Q, Tang F, et al
    Identification of shared key genes in Rheumatoid Arthritis and COVID-19 and their relevance as diagnostic biomarkers and with immune infiltration: New insights from bioinformatics analysis.
    PLoS One. 2025;20:e0333886.
    PubMed         Abstract available

  21. SHOBHA M, Morgan K, Tan MP
    Exploring the social and emotional impact of COVID-19 on older residents of the Greater Klang Valley, Malaysia: A qualitative study.
    PLoS One. 2025;20:e0332610.
    PubMed         Abstract available

  22. DOMINGUES RMSM, Herzog RSA, Dias MAB, Francisco RPV, et al
    Effects of human development, primary care coverage and the COVID-19 pandemic on the fertility rate among adolescents in Brazil in the period 2012-2021.
    PLoS One. 2025;20:e0327656.
    PubMed         Abstract available

  23. GUO L, Jiang L, Huang H
    A longitudinal study of four-year changes in physical fitness among university students before and after COVID-19: 2019-2022.
    PLoS One. 2025;20:e0334088.
    PubMed         Abstract available

  24. BEAUCHAMP M, Farley C, Kirkwood R, Jones A, et al
    Functional recovery 2-years after hospitalization for COVID-19: Insights from the COREG-FR extension study.
    PLoS One. 2025;20:e0334212.
    PubMed         Abstract available

  25. LEE R, Cho J, Bae D, Albers L, et al
    Prospective associations of COVID-related stress with vaping nicotine and cannabis among high school students: Mediated by vaping susceptibility.
    PLoS One. 2025;20:e0334159.
    PubMed         Abstract available

  26. AXEN I, Weiss N, Skillgate E
    Health aspects and lifestyle of licensed manual therapists during the COVID-19 pandemic in Sweden: The CAMP cohort study.
    PLoS One. 2025;20:e0327600.
    PubMed         Abstract available

  27. CHESENG A, Vattanasit U, Kongpran J, Thanapop C, et al
    Environmental health management in local community isolation facilities during COVID-19 pandemic: A case study in Nakhon Si Thammarat, Thailand.
    PLoS One. 2025;20:e0333638.
    PubMed         Abstract available

  28. NGO VK, Vu TT, Sunseri V, Sharma S, et al
    Community's perceptions of the police during COVID-19 in Harlem, New York, a predominantly Black community: Social and geographical dimensions.
    PLoS One. 2025;20:e0329027.
    PubMed         Abstract available

  29. AUSTIN LC, Gomes MN, Chavez S, Degano C, et al
    Foundations under pressure: Qualitative interviews on the impact of prolonged pandemic and public health measures on Ontario youth and young adults.
    PLoS One. 2025;20:e0307423.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  30. MCKELLAR J, Cadenes J, Garcia de Gracia F, Aube C, et al
    Human MX1 orchestrates the cytoplasmic sequestration of neosynthesized influenza A virus vRNPs.
    Proc Natl Acad Sci U S A. 2025;122:e2418935122.
    PubMed         Abstract available

  31. LIU S, Yan L, Du W, Liu W, et al
    Manifold-constrained nucleus-level denoising diffusion model for structure-based drug design.
    Proc Natl Acad Sci U S A. 2025;122:e2415666122.
    PubMed         Abstract available


    Vaccine

  32. ROMANOVA J, Krokhin A, Ferko B, Pleimes D, et al
    Protective efficacy of the UniFluVec influenza vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 (H5N1) strain in ferrets.
    Vaccine. 2025;65:127795.
    PubMed         Abstract available

  33. ANDERSON KM, Nowak GJ, Cacciatore MA, Rohani P, et al
    Understanding influenza vaccination attitudes and behaviors: An assessment of health decision-making preferences.
    Vaccine. 2025;65:127804.
    PubMed         Abstract available

  34. ALMEIDA GG, Pinto JA, Pinto PM, da Silva LB, et al
    Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19.
    Vaccine. 2025;64:127756.
    PubMed         Abstract available

  35. HUMPHREYS J, Blake A, Nicolay N, Braeye T, et al
    Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
    Vaccine. 2025;64:127752.
    PubMed         Abstract available

  36. CUYPERS L, Dambre C, Desmet S
    Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes.
    Vaccine. 2025;64:127763.
    PubMed         Abstract available

  37. INOUE S, Fuji K
    The mutual cyclical influence of internet information and vaccination intention on post-dissemination vaccination: A longitudinal study during the availability period of COVID-19 booster shots.
    Vaccine. 2025;64:127741.
    PubMed         Abstract available

  38. HAMONIC G, Pastural E, Arora S, Lew J, et al
    Safety and immunogenicity of COVAC-2, a Sepivac SWE adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.
    Vaccine. 2025;64:127748.
    PubMed         Abstract available

  39. TURJEMAN A, Shochat T, Drozdinsky G, Leibovici L, et al
    Disparities and temporal trends in pneumococcal vaccination uptake among older adults in the Israeli population: A population-based retrospective cohort study.
    Vaccine. 2025;64:127765.
    PubMed         Abstract available

  40. VAN BEEK LF, He X, Koks MS, van der Gaast-de Jongh CE, et al
    Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.
    Vaccine. 2025;64:127749.
    PubMed         Abstract available

  41. HUANG W, Xu M, Diao Z, Chen J, et al
    Vaccination coverage by age 24 months among children born in 2020 and 2021 in China, during the COVID-19 pandemic: A study based on the national immunization information system.
    Vaccine. 2025;64:127717.
    PubMed         Abstract available

  42. YANG Y, Jin SW, Lee S, Lartey S, et al
    Understanding vaccine willingness in post-COVID America: Key determinants and demographic differences.
    Vaccine. 2025;64:127740.
    PubMed         Abstract available

  43. WETZKE M, Lange M, Beinhauer K, Rope E, et al
    Immunization acceptance after broad recommendation for RSV prophylaxis: Results from a cross-sectional study in Germany.
    Vaccine. 2025;64:127716.
    PubMed         Abstract available

  44. DIEMERT DJ, Graciaa DS, Zhang B, Rouphael NG, et al
    Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.
    Vaccine. 2025;64:127718.
    PubMed         Abstract available

  45. BALMUTH A, Brennan T, Ashebir S, D'Ambrosio L, et al
    Examining the contributions of demographic variables to vaccination uptake among the U.S. aged 50.
    Vaccine. 2025;64:127711.
    PubMed         Abstract available

  46. WANG Y, Ni Y, Leung CMC, Ning K, et al
    Longitudinal patterns and predictors of COVID-19 vaccine confidence from pre-vaccine rollout to mass vaccination: A population-based cohort study.
    Vaccine. 2025;64:127736.
    PubMed         Abstract available

  47. ZHAO Y, Zhao Z, Cheng C, Tian M, et al
    A bivalent SARS-CoV-2 subunit vaccine for cats neutralizes both the original ancestral strain and BA.1 Pseudovirus carrying the 453F and 501 T mutation.
    Vaccine. 2025;64:127685.
    PubMed         Abstract available

  48. MUES KE, Zhou CK, Gerber JE, van Hunsel F, et al
    A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic.
    Vaccine. 2025;64:127691.
    PubMed         Abstract available

  49. BOGA DJ, Robinson M, Tirupathi M, Juste RS, et al
    Latent class and time-to-event analyses of social determinants of health and COVID-19 vaccine uptake among Black women living with HIV.
    Vaccine. 2025;64:127649.
    PubMed         Abstract available

  50. ROY DN, Rashid M, Aktar A, Parvin MS, et al
    Potential predictors of COVID-19 booster vaccine confidence among adult people: a cross-sectional analysis amid the Omicron surge in Southern Bangladesh.
    Vaccine. 2025;64:127693.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »